Psyence Biomedical Ltd. Common Shares (PBM)
Stock · NASDAQ · Health Care
$4.22as of 10/16/2026
Price chart
Active signals
PBM Signal Track Record
How signals performed across all stocks →What PBM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 24 | +0.4% | 58% | September 11, 2026 |
| Bollinger Band Breakdown | 12 | -34.9% | 8% | January 20, 2026 |
| Volume Spike | 11 | -23.0% | 36% | September 23, 2026 |
| Any 20-session window (baseline) | -0.1% | 48% |
Computed by MarketWall from daily closing prices since September 27, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PBM
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiar…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 12
- Website
- psyencebiomed.com/contact/
Fundamentals
- 1-day range
- $4.2$4.53
- Market cap
- $13.31M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-98.35
- Dividend yield
- —
- Beta
- 1.68
- Avg. volume
- 83.9K
Psyence Biomedical Ltd. Common Shares Competitors
Chosen by industry and closest market cap.
- PBMPsyence Biomedical Ltd. Common Shares$4.22▼ 2.31%Market cap $13.31MP/E —$1.92$143.5
- GTBPGT Biopharma Inc. Common Stock$7.03▼ 4.48%Market cap $13.35MP/E —$4.91$34.25
- CMMBChemomab Therapeutics Ltd. American Depositary Share$1.26▼ 1.94%Market cap $12.95MP/E —$1.05$3.5
- AEONAEON Biopharma Inc. Class A Common Stock$0.232▼ 4.53%Market cap $13.80MP/E —$0.1772$1.45
- PTNPalatin Technologies Inc. Common Stock$6.02▼ 7.24%Market cap $14.00MP/E 92.55$5.61$31
- VTGNVistagen Therapeutics Inc. Common Stock$0.2▼ 4.76%Market cap $12.59MP/E —$0.198$5.14
- AKTXAkari Therapeutics plc ADS$8.18▼ 7.47%Market cap $14.14MP/E Infinity$3.02$39.64
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PBM Psyence Biomedical Ltd. Common Shares | $13.31M | — | $4.22 | ▼ 2.31% | $1.92$143.5 |
| GTBP GT Biopharma Inc. Common Stock | $13.35M | — | $7.03 | ▼ 4.48% | $4.91$34.25 |
| CMMB Chemomab Therapeutics Ltd. American Depositary Share | $12.95M | — | $1.26 | ▼ 1.94% | $1.05$3.5 |
| AEON AEON Biopharma Inc. Class A Common Stock | $13.80M | — | $0.232 | ▼ 4.53% | $0.1772$1.45 |
| PTN Palatin Technologies Inc. Common Stock | $14.00M | 92.55 | $6.02 | ▼ 7.24% | $5.61$31 |
| VTGN Vistagen Therapeutics Inc. Common Stock | $12.59M | — | $0.2 | ▼ 4.76% | $0.198$5.14 |
| AKTX Akari Therapeutics plc ADS | $14.14M | Infinity | $8.18 | ▼ 7.47% | $3.02$39.64 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Psyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical Ingredientbenzinga · 10/5/2026
- Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade IbogaineYahoo · 10/5/2026
- Psyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical IngredientBenzinga · 10/5/2026
- Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research CorporationYahoo · 9/28/2026
- Psyence Biomedical Unit TIRC Signs Binding Term Sheet With Psyence Labs For An Exclusive License, Supply And Wholesale Distribution Arrangement For Psylabs’ Pharmaceutical-Grade Ibogaine In The U.S.Benzinga · 9/28/2026
- Psyence BioMed Announces Strategic Ibogaine InvestmentYahoo · 9/23/2026
- Psyence Biomedical Agrees To Make Cash Investment Of Up To $5M In Psyence LabsBenzinga · 9/23/2026
- Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine DevelopmentYahoo · 9/14/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 151.3K
- Total value held
- $575.0K
- Institutional holders
- 2
- Unknown151.3K
- Unknown89
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
PBM Secures Exclusive U.S. Ibogaine License Agreements
Psyence Biomedical announced that it has obtained an exclusive U.S. license for ibogaine from Texas Ibogaine Research Corporation. The company also signed a binding term sheet with Psyence Labs to supply and wholesale pharmaceutical‑grade ibogaine in the United States. These agreements give PBM exclusive rights to distribute the compound in the U.S. market, potentially expanding its product portfolio. The stock continues to trade within a broad 52‑week range.
PBM Secures Exclusive U.S. Ibogaine License Agreements. Psyence Biomedical announced that it has obtained an exclusive U.S. license for ibogaine from Texas Ibogaine Research Corporation. The company also signed a binding term sheet with Psyence Labs to supply and wholesale pharmaceutical‑grade ibogaine in the United States. These agreements give PBM exclusive rights to distribute the compound in the U.S. market, potentially expanding its product portfolio. The stock continues to trade within a broad 52‑week range.